StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
Publishing Date
2023 - 11 - 13
1
2023 - 11 - 06
1
2023 - 10 - 19
1
2023 - 05 - 15
1
2023 - 04 - 24
1
2023 - 01 - 13
1
2022 - 05 - 09
1
2022 - 04 - 25
1
2021 - 11 - 05
2
2021 - 11 - 02
1
2021 - 10 - 18
1
2021 - 03 - 15
1
2021 - 02 - 12
1
2021 - 01 - 22
1
2020 - 12 - 07
1
Sector
Health technology
16
Tags
Association
1
Biotech-beach
5
Biotechnology
1
Blood
2
Calendar of events
1
Cibmtr
2
Clinical-trials-phase-i
1
Disease
2
Events
2
Immunology
1
Lupus
2
Meeting
4
N/a
3
Phase 1
2
Phase 1b
2
Phase 2b
2
Positive
3
Presentation
6
Research
3
Study
2
T-cell
1
Therapy
2
Treatment
1
Entities
Abbvie inc.
27
Actinium pharmaceuticals, inc.
21
Affimed n.v.
28
Allogene therapeutics, inc.
21
Alnylam pharmaceuticals, inc.
23
Amgen inc.
17
Argenx se
15
Arrival
34
Athena consumer acquisition corp.
15
B2gold corp
16
Bausch health companies inc.
19
Beigene, ltd.
14
Bristol-myers squibb company
25
Cellectis s.a.
19
Clearside biomedical, inc.
22
Cytokinetics, incorporated
16
Ecopetrol s.a.
24
Eli lilly and company
65
Equillium, inc.
16
Ericsson
24
Fortress biotech, inc.
14
Galectin therapeutics inc.
14
Genfit s.a.
19
Genmab a/s
24
Grupo aeroportuario del pacifico, s.a. de c.v.
24
Immix biopharma, inc.
16
In8bio inc
14
Incyte corporation
40
Iovance biotherapeutics, inc.
17
Jaguar health, inc.
16
Jazz pharmaceuticals plc
16
Johnson & johnson
37
Kymera therapeutics, inc.
15
Lithium corp
18
Medicenna therapeutics corp.
22
Medicinova, inc.
15
Morgan stanley
37
Nextera energy partners, lp
18
Nextera energy, inc.
19
Northrop grumman corporation
28
Novartis ag
16
Novo nordisk a/s
18
Ocular therapeutix, inc.
16
Ocuphire pharma inc.
15
Oncolytics biotech inc.
23
Orange
144
Otonomy, inc.
17
Phio pharmaceuticals corp.
16
Regenxbio inc.
15
Sana biotechnology inc
18
Sanofi
86
Seagen inc.
16
Sutro biopharma, inc.
17
Tg therapeutics, inc.
26
Tscan therapeutics inc
20
Verizon communications inc.
15
Wisekey international holding ag
15
X financial
15
Xencor, inc.
16
Zynerba pharmaceuticals, inc.
22
Symbols
EQ
16
Exchanges
Nasdaq
16
Crawled Date
2023 - 11 - 13
1
2023 - 11 - 06
1
2023 - 10 - 19
1
2023 - 05 - 15
1
2023 - 04 - 24
1
2023 - 01 - 13
1
2022 - 05 - 09
1
2022 - 04 - 25
1
2021 - 11 - 05
2
2021 - 11 - 02
1
2021 - 10 - 18
1
2021 - 03 - 15
1
2021 - 02 - 12
1
2021 - 01 - 22
1
2020 - 12 - 07
1
Crawled Time
12:00
1
13:00
5
13:01
2
13:15
2
13:30
1
14:00
2
17:00
2
20:03
1
Source
www.biospace.com
12
www.globenewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
meeting
entities :
Equillium, inc.
save search
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
Published:
2023-11-13
(Crawled : 17:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
273.28%
|
O:
0.08%
H:
6.43%
C:
0.81%
positive
meeting
study
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
Published:
2023-11-06
(Crawled : 14:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
270.0%
|
O:
-4.0%
H:
8.29%
C:
3.13%
meeting
study
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
Published:
2023-10-19
(Crawled : 13:30)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
172.86%
|
O:
1.28%
H:
0.0%
C:
-2.93%
presentation
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
Published:
2023-05-15
(Crawled : 14:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
217.87%
|
O:
3.09%
H:
25.0%
C:
13.33%
association
presentation
meeting
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Published:
2023-04-24
(Crawled : 13:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
200.81%
|
O:
5.69%
H:
7.18%
C:
-5.74%
presentation
blood
meeting
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published:
2023-01-13
(Crawled : 17:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
56.78%
|
O:
4.24%
H:
0.0%
C:
-10.57%
cibmtr
presentation
therapy
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
Published:
2022-05-09
(Crawled : 13:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-26.88%
|
O:
0.0%
H:
0.0%
C:
-5.93%
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
Published:
2022-04-25
(Crawled : 13:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-38.13%
|
O:
-0.67%
H:
3.2%
C:
-2.36%
cibmtr
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
Published:
2021-11-05
(Crawled : 13:15)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-72.05%
|
O:
-1.81%
H:
3.54%
C:
0.15%
phase 1
phase 1b
lupus
phase 2b
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
Published:
2021-11-05
(Crawled : 13:15)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-72.05%
|
O:
-1.81%
H:
3.54%
C:
0.15%
phase 1
immunology
phase 1b
phase 2b
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
Published:
2021-11-02
(Crawled : 13:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-70.3%
|
O:
1.44%
H:
4.11%
C:
2.37%
lupus
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
Published:
2021-10-18
(Crawled : 13:00)
- biospace.com/
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-68.86%
|
O:
-2.36%
H:
1.9%
C:
-1.38%
presentation
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
Published:
2021-03-15
(Crawled : 12:00)
- globenewswire.com
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-76.61%
|
O:
3.03%
H:
6.75%
C:
1.84%
presentation
disease
blood
positive
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Published:
2021-02-12
(Crawled : 20:03)
- globenewswire.com
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
Email alert
Add to watchlist
disease
treatment
positive
therapy
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
Published:
2021-01-22
(Crawled : 13:01)
- globenewswire.com
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-67.66%
|
O:
1.75%
H:
4.81%
C:
3.26%
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition
Published:
2020-12-07
(Crawled : 13:01)
- globenewswire.com
EQ
|
$1.77
-1.12%
-1.13%
74K
|
Health Technology
|
-62.24%
|
O:
0.0%
H:
0.41%
C:
-3.67%
t-cell
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.